UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


Washington,
D. C. 20549


FORM 10-Q/A





Amendment No. 1





☒
Quarterly report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934





For
the quarterly period ended June 30,
2020





☐
Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934





For
the transition period from to





Commission
File Number: 0-28666





AMERICAN BIO MEDICA CORPORATION


(Exact
name of registrant as specified in its charter)





New York

14-1702188(State
or other jurisdiction of incorporation or
organization)

(I.R.S.
Employer Identification No.)





122 Smith Road, Kinderhook, New York

12106(Address
of principal executive offices)

(Zip
Code)





518-758-8158


(Registrant's
telephone number, including area code)





Securities
registered pursuant to Section 12(b) of the Act:





Title of each class
Trading Symbol(s)
Name of each exchange on which registeredCommon
Stock
ABMC
OTC
Markets Pink





Indicate
by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or such
shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for
the past 90 days





☒
Yes   ☐
No





Indicate
by check mark whether the registrant has submitted electronically
and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405
of Regulation S-T (§232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files) ☒ Yes ☐
No





Indicate
by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of “large accelerated
filer”, “accelerated filer” and “smaller
reporting company” in Rule 12b-2 of the Exchange
Act





Large
accelerated filer
☐
Accelerated
filer
☐Non-accelerated
filer
☐
Smaller
reporting company
☒Emerging
growth company
☐





If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act  
☐





Indicate
by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act) ☐ Yes  ☐
No





Indicate
the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date:





35,953,476
Common Shares as of September 15, 2020














Explanatory Note





This
Amendment No. 1 (the "Amendment") to the Quarterly Report on Form
10-Q of American Bio Medica Corporation (the "Company") for the
quarter ended June 30, 2020, originally filed with the Securities
and Exchange Commission on September 15, 2020 (the "Original Form
10-Q"), is being filed solely to correct a typographical error on
the cover page of the Original Form 10-Q. More specifically, the
“No” box was checked instead of the “Yes”
box for the question regarding whether the registrant has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 (the “Act”) during the
preceding 12 months as the Company has filed all reports required
under the Act.





No
other parts of the Original Form 10-Q presented incorrect share
information.





This
Amendment is limited in scope to the correction described above and
does not amend, update, or change any other items or disclosures
contained in the Original Form 10-Q. Accordingly, all other items
that remain unaffected are omitted in this filing. Except as
described in the preceding paragraph, this Amendment does not
update any of the information contained in the Original Form 10-Q,
which continues to speak as of the original filing date of the
Original Form 10-Q.





This
Amendment contains new certifications by the Company’s
principal executive officer/principal financial officer, which are
being filed as exhibits to the Amendment.











Item 6. Exhibits





31.1/31.2
Rule
13a-14(a)/15d-14(a) Certification of Chief Executive Officer/Chief
Financial Officer32.1/32.2
Certification
of the Chief Executive Officer/Chief Financial Officer pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002























SIGNATURES





In
accordance with the requirements of the Exchange Act, the
registrant has caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.








AMERICAN BIO MEDICA
CORPORATIONDated: September
25, 2020
By:
/s/ Melissa A.
WaterhouseMelissa
A. WaterhouseChief Executive
Officer (Principal Executive Officer)
Principal Financial
Officer
Principal
Accounting Officer